memantine has been researched along with Bipolar Disorder in 28 studies
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to examine the effects of memantine as an adjuvant treatment for obsessive compulsive (OC) symptoms in patients with bipolar disorder (BD) type I, manic phase." | 9.24 | Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. ( Ghanizadeh, A; Jahromi, LR; Mowla, A; Sahraian, A, 2017) |
| " Lamotrigine, an anticonvulsant which decreases presynaptic glutamate release, has been shown to be effective in the depressive phase of bipolar disorder (BD-D); however, only 40-50% of patients have a full response." | 9.16 | Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. ( Anand, A; Barkay, G; Ghosh, S; Gunn, AD; Karne, HS; Mathew, SJ; Nurnberger, JI, 2012) |
| "Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports." | 8.93 | Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 8.91 | Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. ( Amit, BH; Brett, D; Caddy, C; Cipriani, A; Diamond, PR; Hamadi, L; Hawton, K; Jochim, J; McCloud, TL; McShane, R; Rendell, JM; Shuttleworth, C, 2015) |
| "Memantine added substantial long-term benefits by preventing or ameliorating depressive as well as mania-like morbidity in previously consistently poorly responsive patients with bipolar disorder." | 7.81 | Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder. ( Baldessarini, RJ; De Chiara, L; Girardi, P; Koukopoulos, A; Koukopoulos, AE; Serra, G; Tondo, L, 2015) |
| "We have recently reported that memantine has a clinically relevant antimanic and long-lasting mood-stabilizing effect in treatment-resistant bipolar disorders, both as augmenting agent and as monotherapy." | 7.80 | Memantine in the treatment and prophylaxis of bipolar II disorder and comorbid fibromyalgia: a case report. ( DE Chiara, L; Kahn, DA; Koukopoulos, A; Koukopoulos, AE; Serra, G, 2014) |
| "We have recently provided preliminary clinical observations indicating that memantine, as augmenting agent, was associated with a meaningful antimanic and mood-stabilizing effect in treatment-resistant bipolar disorders." | 7.78 | The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. ( Koukopoulos, A; Koukopoulos, AE; Reginaldi, D; Serra, G, 2012) |
| "Memantine is an NMDA receptor antagonist with anti-inflammatory effects." | 6.84 | Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. ( Chang, HH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, SY; Lu, RB; Wang, TY; Yang, YK, 2017) |
| "The aim of this study is to examine the effects of memantine as an adjuvant treatment for obsessive compulsive (OC) symptoms in patients with bipolar disorder (BD) type I, manic phase." | 5.24 | Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. ( Ghanizadeh, A; Jahromi, LR; Mowla, A; Sahraian, A, 2017) |
| "Memantine, a noncompetitive N-methyl-d-aspartate receptor antagonist with a mood-stabilizing effect, and an association between bipolar disorder and proinflammatory cytokine levels have been reported." | 5.19 | The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial. ( Chang, YH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Wang, YS; Yang, YK; Yeh, TL, 2014) |
| " Lamotrigine, an anticonvulsant which decreases presynaptic glutamate release, has been shown to be effective in the depressive phase of bipolar disorder (BD-D); however, only 40-50% of patients have a full response." | 5.16 | Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. ( Anand, A; Barkay, G; Ghosh, S; Gunn, AD; Karne, HS; Mathew, SJ; Nurnberger, JI, 2012) |
| "As a non-competitive N-methyl-d-aspartate receptor antagonist, memantine has been used to treat major mental disorders including schizophrenia, bipolar disorder, and major depressive disorder (MDD)." | 5.01 | Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. ( Cai, DB; He, SH; Ng, CH; Ning, YP; Peng, XJ; Ungvari, GS; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W; Zhou, YL; Zhu, XM, 2019) |
| "We conducted a systematic review and meta-analysis on whether memantine was beneficial for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD)." | 4.95 | A Meta-Analysis of Memantine for Depression. ( Iwata, N; Kishi, T; Matsunaga, S, 2017) |
| "Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports." | 4.93 | Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 4.91 | Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. ( Amit, BH; Brett, D; Caddy, C; Cipriani, A; Diamond, PR; Hamadi, L; Hawton, K; Jochim, J; McCloud, TL; McShane, R; Rendell, JM; Shuttleworth, C, 2015) |
| "Memantine added substantial long-term benefits by preventing or ameliorating depressive as well as mania-like morbidity in previously consistently poorly responsive patients with bipolar disorder." | 3.81 | Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder. ( Baldessarini, RJ; De Chiara, L; Girardi, P; Koukopoulos, A; Koukopoulos, AE; Serra, G; Tondo, L, 2015) |
| " These observations led us to suggest - and later confirm - with preliminary clinical observations that memantine may have an acute antimanic and a long-lasting mood-stabilizing effect in treatment-resistant bipolar disorder patients." | 3.81 | Memantine prevents "bipolar-like" behavior induced by chronic treatment with imipramine in rats. ( Canu, D; Demontis, F; Falconi, M; Serra, G, 2015) |
| "We have recently reported that memantine has a clinically relevant antimanic and long-lasting mood-stabilizing effect in treatment-resistant bipolar disorders, both as augmenting agent and as monotherapy." | 3.80 | Memantine in the treatment and prophylaxis of bipolar II disorder and comorbid fibromyalgia: a case report. ( DE Chiara, L; Kahn, DA; Koukopoulos, A; Koukopoulos, AE; Serra, G, 2014) |
| "We have recently provided preliminary clinical observations indicating that memantine, as augmenting agent, was associated with a meaningful antimanic and mood-stabilizing effect in treatment-resistant bipolar disorders." | 3.78 | The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. ( Koukopoulos, A; Koukopoulos, AE; Reginaldi, D; Serra, G, 2012) |
| "Because BD-II and alcohol dependence are neurodegenerative disorders, agents with anti-inflammatory and neurotrophic effects might provide effective therapy." | 2.87 | Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study. ( Chang, YH; Chen, KC; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Yang, YK, 2018) |
| "Memantine is an NMDA receptor antagonist with anti-inflammatory effects." | 2.84 | Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. ( Chang, HH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, SY; Lu, RB; Wang, TY; Yang, YK, 2017) |
| "Memantine is a non-competitive N-methyl-d-asparate (NMDA) receptor antagonist with a mood-stabilizing effect." | 2.79 | Genotype variant associated with add-on memantine in bipolar II disorder. ( Chang, YH; Chen, SH; Chen, SL; Chu, CH; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, CL; Wang, LJ; Yang, YK; Yeh, TL, 2014) |
| "Inflammation is thought to be involved in the pathophysiology of bipolar disorder (BP) and metabolic syndrome." | 2.78 | Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder. ( Chang, YH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Wang, YS; Yang, YK; Yeh, TL, 2013) |
| "Memantine is a noncompetitive NMDA receptor antagonist." | 2.78 | Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. ( Chang, YH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, YS; Yang, YK; Yeh, TL, 2013) |
| "In a pilot study, 29 outpatients with bipolar depression on a stable lamotrigine dose regimen received placebo or memantine pills daily (titrated up by 5 mg week⁻¹ to 20 mg) in a randomized, double-blind, parallel group, 8 week study." | 2.78 | Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression. ( Anand, A; Bies, RR; Shekhar, A; Stevens, J, 2013) |
| " Ouabain-induced hyperlocomotion was normalized with acute and chronic lithium and chronic use of memantine." | 1.37 | Memantine reduces mania-like symptoms in animal models. ( Banerjee, P; El-Mallakh, RS; Gao, Y; Herman, L; Hougland, T; Lei, Z; Lord, J; Payne, RS; Schurr, A, 2011) |
| "The authors report 2 cases, in Alzheimer's disease and vascular dementia, in which erotomania emerged in the early stage of the underlying disorder." | 1.32 | Erotomania variants in dementia. ( Brüne, M; Schröder, SG, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 23 (82.14) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Link, PE | 1 |
| Lu, RB | 10 |
| Wang, TY | 6 |
| Lee, SY | 9 |
| Chang, YH | 8 |
| Chen, SL | 9 |
| Tsai, TY | 1 |
| Chen, PS | 8 |
| Huang, SY | 9 |
| Tzeng, NS | 8 |
| Lee, IH | 8 |
| Chen, KC | 3 |
| Yang, YK | 9 |
| Hong, JS | 9 |
| Chang, HH | 1 |
| Wang, LJ | 6 |
| Zheng, W | 1 |
| Zhu, XM | 1 |
| Zhang, QE | 1 |
| Cai, DB | 1 |
| Yang, XH | 1 |
| Zhou, YL | 1 |
| Ungvari, GS | 1 |
| Ng, CH | 1 |
| He, SH | 1 |
| Peng, XJ | 1 |
| Ning, YP | 1 |
| Xiang, YT | 1 |
| Wang, YS | 3 |
| Yeh, TL | 5 |
| Serra, G | 11 |
| De Chiara, L | 3 |
| Koukopoulos, A | 6 |
| Chen, SH | 3 |
| Chu, CH | 3 |
| Wang, CL | 1 |
| Koukopoulos, AE | 3 |
| Kahn, DA | 1 |
| Tondo, L | 1 |
| Girardi, P | 1 |
| Baldessarini, RJ | 1 |
| Demontis, F | 1 |
| Falconi, M | 1 |
| Canu, D | 1 |
| McCloud, TL | 1 |
| Caddy, C | 1 |
| Jochim, J | 1 |
| Rendell, JM | 1 |
| Diamond, PR | 1 |
| Shuttleworth, C | 1 |
| Brett, D | 1 |
| Amit, BH | 1 |
| McShane, R | 1 |
| Hamadi, L | 1 |
| Hawton, K | 1 |
| Cipriani, A | 1 |
| Veronese, N | 1 |
| Solmi, M | 1 |
| Luchini, C | 1 |
| Stubbs, B | 1 |
| Zaninotto, L | 1 |
| Correll, CU | 1 |
| Li, CL | 1 |
| Chung, YL | 1 |
| Hsieh, TH | 1 |
| Sahraian, A | 1 |
| Jahromi, LR | 1 |
| Ghanizadeh, A | 1 |
| Mowla, A | 1 |
| Kishi, T | 1 |
| Matsunaga, S | 1 |
| Iwata, N | 1 |
| Reginaldi, D | 2 |
| Sani, G | 1 |
| Canan, F | 1 |
| Ataoglu, A | 1 |
| Gao, Y | 1 |
| Payne, RS | 1 |
| Schurr, A | 1 |
| Hougland, T | 1 |
| Lord, J | 1 |
| Herman, L | 1 |
| Lei, Z | 1 |
| Banerjee, P | 1 |
| El-Mallakh, RS | 1 |
| Anand, A | 2 |
| Gunn, AD | 1 |
| Barkay, G | 1 |
| Karne, HS | 1 |
| Nurnberger, JI | 1 |
| Mathew, SJ | 1 |
| Ghosh, S | 1 |
| Stevens, J | 1 |
| Bies, RR | 1 |
| Shekhar, A | 1 |
| Brüne, M | 1 |
| Schröder, SG | 1 |
| Teng, CT | 1 |
| Demetrio, FN | 1 |
| Zdanys, K | 1 |
| Tampi, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Series Studies of Bipolar Disorder-Valproate add-on Memantine Treatment[NCT01188148] | Phase 2/Phase 3 | 219 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for memantine and Bipolar Disorder
| Article | Year |
|---|---|
Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials.
Topics: Bipolar Disorder; Cognition; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combinat | 2019 |
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cytidine; Depression; Excitatory Amino Acid Antagoni | 2015 |
Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions.
Topics: Adult; Bipolar Disorder; Case-Control Studies; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2016 |
A Meta-Analysis of Memantine for Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Memantine | 2017 |
A systematic review of off-label uses of memantine for psychiatric disorders.
Topics: Anxiety; Bipolar Disorder; Bulimia Nervosa; Child; Child Development Disorders, Pervasive; Depressio | 2008 |
12 trials available for memantine and Bipolar Disorder
| Article | Year |
|---|---|
Add-on memantine may improve cognitive functions and attenuate inflammation in middle- to old-aged bipolar II disorder patients.
Topics: Aged; Bipolar Disorder; Cognition; Double-Blind Method; Drug Therapy, Combination; Humans; Inflammat | 2021 |
Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; C-Reactive Protein; Female; Humans; Lipids; Male; Memanti | 2017 |
Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study.
Topics: Alcohol Drinking; Alcoholism; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; | 2018 |
Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder.
Topics: Adult; Biomarkers; Bipolar Disorder; Cytokines; Double-Blind Method; Drug Therapy, Combination; Fema | 2013 |
Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Double-Bli | 2013 |
Genotype variant associated with add-on memantine in bipolar II disorder.
Topics: Adult; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Double-Blind Method; Drug Therapy, Combi | 2014 |
The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cytokines; Double-Blind Method; Drug Therapy, Combination | 2014 |
Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder.
Topics: Adolescent; Adult; Biomarkers; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cytokines; Dextr | 2016 |
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Topics: Adjuvants, Pharmaceutic; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Dis | 2017 |
Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Synergism; Excitatory Amino Acid Antagonists; Female | 2010 |
Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depression; Dopamine Agents; Doubl | 2012 |
Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bayes Theorem; Bipolar Disorder; Dopamine Agents; Double-B | 2013 |
11 other studies available for memantine and Bipolar Disorder
| Article | Year |
|---|---|
Memantine for bipolar disorder: A case report.
Topics: Bipolar Disorder; Excitatory Amino Acid Antagonists; Humans; Memantine | 2021 |
Antimanic and long-lasting mood stabilizing effect of memantine in bipolar I mood disorder: two case reports.
Topics: Adult; Affect; Antimanic Agents; Bipolar Disorder; Female; Humans; Memantine; Middle Aged; Psychiatr | 2013 |
Memantine in the treatment and prophylaxis of bipolar II disorder and comorbid fibromyalgia: a case report.
Topics: Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agents; Female; Fi | 2014 |
Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder.
Topics: Adult; Bipolar Disorder; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Male; | 2015 |
Memantine prevents "bipolar-like" behavior induced by chronic treatment with imipramine in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bipolar Disorder; Depression; Imipramine; Male; Me | 2015 |
Memantine-related psychotic symptoms in a patient with bipolar disorder.
Topics: Alzheimer Disease; Antimanic Agents; Bipolar Disorder; Donepezil; Drug Interactions; Excitatory Amin | 2010 |
Memantine reduces mania-like symptoms in animal models.
Topics: Action Potentials; Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; Dose-Respons | 2011 |
The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial.
Topics: Adult; Affect; Aged; Aged, 80 and over; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; E | 2012 |
Neuroprotective and neurogenesis agent for treating bipolar II disorder: add-on memantine to mood stabilizer works.
Topics: Antimanic Agents; Bipolar Disorder; Brain; Brain-Derived Neurotrophic Factor; Dopamine Agents; Human | 2012 |
Erotomania variants in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bipolar Disorder; Delusions; Dementia, Vascular; Dopamin | 2003 |
Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder.
Topics: Acute Disease; Adult; Bipolar Disorder; Drug Administration Schedule; Drug Resistance; Excitatory Am | 2006 |